Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Chiauranib in ES-SCLC
NCT05505825Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cadonilimab in small cell lung cancer (SCLC), sponsored by Akeso, Inc.. Started Aug 2022; status: completed.
02
Drugs
cadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05505825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505825.